RNAi’s Drugs
Pharmaceutical giant Merck’s purchase last fall of Sirna, a San Francisco biotech company specializing in RNA interference (RNAi), was just the latest indication that the technology is gaining momentum. Researchers are currently trying to use RNAi to do everything from treat flu to permanently remove hair. In RNAi therapy, small pieces of double-stranded RNA shut down the genes whose sequences they match. Below is a sampling of RNAi therapies under investigation.
Disease/company
Approach
Status
Age-related macular
degeneration
Acuity (Philadelphia, PA) and Sirna (San Francisco, CA)
Eye injection of RNA that blocks a gene responsible for excessive growth of blood vessels
In phase II clinical trials
Viral lung infections
Alnylam (Cambridge, MA)
Inhalation of drug containing RNA that shuts down viral genes
Therapy for respiratory syncytial virus in phase I trials
Parkinson’s disease
Alnylam and Sirna
Injection of RNA to block a gene that kills brain cells
In preclinical development
Huntington’s disease
Sirna
Injection of RNA to block a gene that kills brain cells
In preclinical development
Hair removal
Sirna
Application of cream containing RNA that blocks hair growth genes
Application to begin clinical trials in progress
Keep Reading
Most Popular
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.